Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.35 USD
Change Today 0.00 / 0.00%
Volume 51.9K
As of 7:40 PM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

celsion corp (CLSN) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/24/14 - $3.73
52 Week Low
01/28/15 - $2.15
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CELSION CORP (CLSN)

celsion corp (CLSN) Related Bloomberg News

View More Bloomberg News

celsion corp (CLSN) Related Businessweek News

No Related Businessweek News Found

celsion corp (CLSN) Details

Celsion Corporation, an oncology drug development company, focuses on the development and commercialization of chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The company’s lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It has a development, product supply, and commercialization agreement with Yakult Honsha Co. Ltd. for ThermoDox; and a commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. for the production of ThermoDox in mainland China, Hong Kong, and Macau. The company was founded in 1982 and is based in Lawrenceville, New Jersey.

28 Employees
Last Reported Date: 03/12/15
Founded in 1982

celsion corp (CLSN) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $462.4K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $368.5K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $446.9K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $154.7K
Compensation as of Fiscal Year 2014.

celsion corp (CLSN) Key Developments

Celsion Completes Offering; Mulls Acquisitions

Celsion Corp. (NasdaqCM:CLSN) has completed a follow-on equity offering in the amount of $8.03 million. The company will use all or a portion of the net proceeds from this offering to fund possible investments in, or acquisitions of, complementary businesses, technologies or products.

Celsion Corporation Announces Preclinical Data Demonstrating Lung Specific Delivery of microRNA-145 Inhibitor Using Novel TheraSilence™ Platform

Celsion Corporation reported the publication of an abstract in the prestigious Journal of Controlled Release summarizing findings from a preclinical study confirming effective delivery of RNA to lung cells. In the study, the Company's TheraSilence technology platform safely and effectively delivered an inhibitor of microRNA-145 (miR-145) in a well-established model of severe occlusive pulmonary arterial hypertension (PAH). Increased expression of miR-145 has been linked to the development and progression of PAH in humans. Treatment was associated with significant delivery of miR-145 inhibitor in the lung, inhibition of miR-145 levels and reversal of the pulmonary hypertension associated with the advanced stages of the disease leading to a normalization of cardiovascular function. This preclinical program was conducted in collaboration with Dr. William Gerthoffer at the University of South Alabama.

Celsion Corp. Announces ASCO2015 GEN-1 Immunotherapy Phase 1B Results in Ovarian Cancer Presentation

Celsion Corp. announced that results from its Phase Ib trial for GEN-1 in platinum-resistant ovarian cancer will be presented in poster session at the 2015 American Society of Clinical Oncology (ASCO) meeting in Chicago on May 30, 2015. GEN-1 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system, which enables cell transfection followed by persistent, local secretion of the IL-12 protein. The Phase 1b dose escalating study enrolled 16 patients with platinum-resistant ovarian cancer and evaluated the safety, tolerability and efficacy of GEN-1 in combination with pegylated doxorubicin as well as the effect of intraperitoneal injection of GEN-1 on IL-12 and tumor cytokine levels. Patients received pegylated liposomal doxorubicin on day 1 and GEN-1 on days 1, 8, 15 and 22. This treatment regimen was repeated every 28 days in the absence of disease progression or unacceptable toxicity. The findings demonstrated an overall clinical benefit of 57% for all treatment arms, with a partial response (PR) rate of 21% and a stable disease (SD) rate of 36%. The overall clinical benefit observed at the high dose level was 86% (PR=29%, SD=57%). GEN-1 was well tolerated, with no dose limiting toxicities and no overlapping toxicities between GEN-1, its subsequent immune system activation and pegylated doxorubicin.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLSN:US $2.35 USD 0.00

CLSN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Medifocus Inc C$0.12 CAD 0.00
Perseon Corp $1.85 USD +0.07
View Industry Companies

Industry Analysis


Industry Average

Valuation CLSN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 94.0x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 30.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELSION CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at